⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 15, 2025

Figure S12 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer

Tianyu Qu Lei Song Jiali Xu Xiyi Lu Dandan Yin Jiali Dai Chen Zhang Renhua Guo Erbao Zhang

View Full Paper

Ask AI

Bookmark

Share

Key Points

Increased glutamine metabolism promotes resistance to EGFR inhibitors in non-small cell lung cancer.
Research indicates that MYLK-AS1 significantly influences TKI resistance mechanisms.
Analysis involved therapeutic assessments of MYLK-AS1 ASO in the context of non-small cell lung cancer.
Findings highlight the potential for targeting MYLK-AS1 to overcome treatment resistance.

Implication

Experiments demonstrate that MYLK-AS1 enhances glutamine metabolism in non-small cell lung cancer, suggesting a link to TKI resistance.

Abstract

Experiments related to the assessment of the therapeutic potential of R162/MYLK-AS1 ASO in TKI resistance.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Qu et al. (2025) studied this question.

synapsesocial.com/papers/68af5bafad7bf08b1eadf33f https://doi.org/10.1158/0008-5472.29919060

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S10 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
2Figure S5 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
3Figure S1 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
4Figure S4 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
5Figure S2 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025